Psychedelic Lived Experiences Summit

Post-protocol care: What happens to participants when structured support from treatment protocol or clinical research ends?

Ethics, accountability and oversight: Where do current safeguards work, where do they fail, and what needs to change?

Safety and emerging risk signals: What warning signs appear during the weeks and months following treatment, and which signals are currently missed?

Measuring what matters: Which outcomes should psychedelic research capture if we want to understand people's lives rather than only clinical endpoints?

Real-world outcomes: How do psychedelic experiences affect relationships, employment, identity, functioning, meaning, and quality of life beyond symptom scores?

Responsibility and continuity of care: What responsibilities do therapists, clinics, researchers, and institutions retain after the formal protocol ends?

Adverse events and challenging experiences: How should difficult outcomes be recognized, understood, documented, and responded to without minimizing or sensationalizing them?

Families, partners, and support networks: How are the people around psychedelic participants affected, and what role should they have in preparation and longer-term support?

Integration, stabilization, and longer-term recovery: What forms of peer or professional support are useful after favourable and/or destabilizing psychedelic experiences, and where are the existing gaps?

Lived experience in research and decision-making: How can patient and participant knowledge become a meaningful input into study design, clinical practice, safety systems, and policy?

Hanifa Nayo Washington

Psychedelic facilitator designing equitable pathways for psychedelic therapy within public healthcare systems, co-director at PMHA Alliance

Leor Roseman, PhD

Senior lecturer and psychedelic researcher at the University of Exeter’s EPIC, founder of Ripples, dedicated to peacebuilding

Laura Zam

MDMA therapy clinical trial participant and caregiver to her husband after post-trial destabilization, award-winning author and resilience speaker

Max Wolff, PhD

Psychologist, researcher, and clinician-scientist in psychotherapy at Humboldt-Universität zu Berlin, Germany

Rosalind Watts, PhD

Clinical psychologist, founder and creator of ACER Integration, former psilocybin clinical lead at Imperial College London

Jesse Gould

U.S. veteran, founder and president of Heroic Hearts Project, a nonprofit supporting psychedelic therapy access for military veterans

Berra Yazar-Klosinski, PhD

Former Chief Scientific Officer at Resilient Pharmaceuticals (formerly Lykos/MAPS PBC), biologist, biotech leader, founder and CEO at Yazar Lab

Joshua White

Lawyer, psychedelic researcher, coach, peer support advocate, founder and executive director of Fireside Project

Becca Kacanda, MS, LPC

Phase 3 MDMA-assisted therapy for PTSD clinical trial participant (active arm), art therapist, peer support facilitator

Henrik Jungaberle, PhD

Researcher and founder and CEO of the MIND Foundation, head of development at OVID Clinic in Berlin, Germany

Anahita Bassir Nia, MD

Addiction psychiatrist and assistant professor at Yale School of Medicine researching psychedelics, substance use disorders, PTSD and neurobiology

Dave Pounds

MDMA-assisted psychotherapy for alcohol use disorder trial participant, trauma and recovery speaker and coach, creator of Design For Life

Jessica Jackson, PhD

Psychologist and vice president at Mental Health America, focused on mental health equity, access, and inclusive systems of care

Jon Nelson

Lived Experience Council member at One Mind, director of lived experience at Motif Neurotech, co-founder at Otherside, mental health advocate

Heidi Allen, PhD

Professor of social work at Columbia University, health policy researcher, developer of psychedelic-assisted therapy training for social workers

Franklin King, MD

Psychiatrist, psychedelic researcher, director of training at MGH’s Center for the Neuroscience of Psychedelics, Harvard Medical School faculty

Bia Labate, PhD

Anthropologist, educator, author, speaker, activist, co-founder and executive director of the Chacruna Institute

Spencer Hawkswell 

CEO of TheraPsil, passionate advocate for legal, medical, and clinical access to psychedelic therapy for Canadians

Chantelle Thomas, PhD

Clinical psychologist and researcher dedicated to post-protocol safety, therapist training, and trauma-focused, ethical psychedelic care

Christopher Nicholas, PhD

Clinical psychologist, psychedelic scientist, and associate professor at the University of Wisconsin studying MDMA and psychedelics for addiction

Jana Sladkova, PhD

Patient with lived experience of group ketamine-assisted psychotherapy and SPRAVATO® (esketamine) treatment for depression

Mourad Wahba, MD

Psychiatrist leading mood disorders research clinic in Newcastle, England, psychedelic trial principal investigator, lecturer, advisor, and educator

Amy Emerson

Former and founding CEO of Resilient Pharmaceuticals (Lykos/MAPS PBC), strategic advisor ensuring patient access to psychedelic therapies 

Rogers Masson

U.S. army veteran, MDMA-assisted psychotherapy for PTSD clinical trial participant, music producer, mental health advocate

Kimberly King

Senior manager of mental health equity and external partnerships for the national office of the Depression and Bipolar Support Alliance (DBSA)

Joe Moore

Co-founder and CEO of Psychedelics Today, co-founder of Psychedelics and Pain Association nonprofit, breathwork facilitator

Sehrish Sayani

Phase 3 MDMA-assisted therapy for PTSD trial participant, advocate for trauma-informed healing, integration, and responsible storytelling

Jérémie Richard, PhD

Clinical psychologist, psychedelic researcher, assistant professor at the University of Ottawa School of Psychology

Sara Garcia Velazquez, MD

Clinical research physician, former associate medical director at Resilient Pharmaceuticals (Lykos/MAPS PBC), quality assurance lead at Changemark

Steve Allgood

Psilocybin-assisted psychotherapy for life-threatening cancer through Canada’s Special Access Program, psychedelic therapy advocate

Amanda Geisinger

Emmy-winning user experience designer, One Mind Lived Experience Council member, IV ketamine and SPRAVATO® with therapy patient

Tehseen Noorani, PhD

Social scientist and psychedelic researcher focused on first-person inquiry at the University of Auckland, New Zealand

Wendy Marussich, PMHNP

Psychiatric nurse practitioner, co-founder of OPENurses, clinician providing TMS and esketamine treatment in outpatient psychiatry

Ari Polivy

Phase 3 MDMA-assisted therapy for PTSD trial participant (placebo then crossover), ibogaine patient, peer supporter, and veterans advocate

Kim Witczak

Global drug safety advocate and speaker, consumer representative on an FDA advisory committee evaluating new drugs and patient safety

Alexander Beiner

Author, journalist and facilitator, executive director of the Breaking Convention, a UK conference on psychedelic medicine and culture

Şerife Tekin, PhD

Associate professor of philosophy and bioethics at SUNY Upstate Medical University, author of Reclaiming the Self in Psychiatry

Britton Rollins

Founder, CEO, and board chair of the National Psychedelics Association, supporting professionals working in psychedelic-assisted care

Taylor West

Executive director of the Healing Advocacy Fund, supporting access to psychedelic therapies through state-regulated programs

Allison Feduccia, PhD

Neuropharmacologist, psychedelic researcher and educator, co-founder of Psychedelic Support, scientific advisor to psychedelic nonprofits

Kathy Neustadt

Phase 3 MDMA-assisted therapy for PTSD clinical trial participant (placebo only), mental health and psychedelic participant rights advocate

Caroline Lilley

Biotech leader focused on patient strategy at AtaiBeckley, strategy consultant at Amandala Neuro, previously with Johnson & Johnson

Ona Praderas

Art therapy student, ACER Integration facilitator, client care at FlowState Therapy ketamine clinic, caregiver and family support advocate

Katie Bourque

Faculty for Yale School of Medicine's Lived Experience Transformational Leadership Academy, former director of operations at the Fireside Project

Madison Nobbs, RN

Registered nurse specializing in emergency nursing and ketamine-assisted therapy for mental health conditions and chronic pain

Lynn Marie Morski, MD, JD

Family and sports medicine physician, president of the Psychedelic Medicine Association, and host of the Psychedelic Medicine Podcast

Melissa Lavasani

Founder and executive director of the Psychedelic Medicine Coalition, advocate for federal psychedelic policy, access, and education

Kerrilee Barrett

Psychoactive substance for PTSD Phase 2 clinical trial participant (double blinded then open label), mental health counsellor

Scarlet Masius

Community strategist and consultant, trained psychedelic peer support facilitator, focused on participatory communities, harm reduction, and public education

Sergio Pérez Rosal, MD

Emergency medicine physician, anesthesiologist, neuroscientist, and researcher specializing in psychedelic medicine, adjunct professor at the University of Ottawa

Anne Katrin Schlag, PhD

Chartered psychologist and head of research at Drug Science, honorary senior fellow at UK's Imperial and King’s, focused on psychedelics, real world data, ethics, and patient access

David Drapkin, LCSW

Psychotherapist, clinical social worker, psychedelic educator, and harm reduction specialist focused on integration, practitioner education, and mental health care

Chelsea Rose Blake, LMFT

Executive director of Zendo Project, licensed therapist and psychedelic harm reduction practitioner with extensive experience in peer support and crisis response

Jazz Glastra, MS

Senior director at BrainFutures, leading U.S. national initiatives on psychedelic therapy access, clinical integration, policy, and mental health system implementation

Melanie Dignam, RSW

Integrative psychotherapist specializing in trauma, IFS, and psychedelic-assisted therapy across ketamine, psilocybin clinical trials, and Canada’s Special Access Program

Additional Moderator

Additional moderator selected to help facilitate the roundtable discussion and contribute relevant perspective and expertise. Full details will be announced soon.

Additional Moderator

Additional moderator selected to help facilitate the roundtable discussion and contribute relevant perspective and expertise. Full details will be announced soon.